

# Valeo Pharma to Host Second Quarter 2022 Results Conference Call / Webcast

written by Igor Makarov | June 8, 2022

June 8, 2022 ([Source](#)) – [Valeo Pharma Inc.](#) (TSX: [VPH](#)) (OTCQB: [VPHIF](#)) (FSE: [VP2](#)) (“**Valeo**” or the “**Company**”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2022 on Tuesday June 14, 2022 after market close. The Company will host a conference call to discuss those results and highlights on Wednesday June 15, 2022 at 8.30am (ET).

Conference ID:	49147207
Date:	Wednesday, June 15, 2022
Time:	8:30am ET
Dial-in numbers:	1-888-664-6392 or 416-764-8659
Audio replay numbers:	1-888-390-0541 or 416-764-8677
Replay code:	147207#

A live audio webcast of the conference call will be available via:

[https://produceredition.webcasts.com/starthere.jsp?ei=1553257&tp\\_key=74c181ca17](https://produceredition.webcasts.com/starthere.jsp?ei=1553257&tp_key=74c181ca17)

## About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory diseases,

Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit [www.valeopharma.com](http://www.valeopharma.com) and follow us on [LinkedIn](#) and [Twitter](#).

### **Forward Looking Statements**

This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

SOURCE Valeo Pharma Inc. 

For further information: Steve Saviuk, CEO, 514-693-8830, [saviuk@valeopharma.com](mailto:saviuk@valeopharma.com) or Luc Mainville, Senior Vice-President and Chief Financial Officer, 514-693-8854, [mainville@valeopharma.com](mailto:mainville@valeopharma.com) or Frederic Dumais, Director, Communications and Investor Relations, 514-782-8803, [dumais@valeopharma.com](mailto:dumais@valeopharma.com)